Benzodiazepine Addiction: Definition, Symptoms, Effects, Causes, and Treatment

Benzodiazepines are a class of central nervous system depressant medications that amplify gamma-aminobutyric acid (GABA), the brain's principal inhibitory neurotransmitter, at the GABA-A receptor. Prescribers use the class to treat anxiety, panic disorder, insomnia, seizure disorders, muscle spasm and acute alcohol withdrawal, and the Drug Enforcement Administration places every marketed benzodiazepine in Schedule IV of the Controlled Substances Act. The New Jersey Office of the Chief State Medical Examiner recorded benzodiazepines in 421 of 2,954 confirmed drug-related deaths statewide in 2020, and in 29 of the 164 such deaths in Bergen County.

Symptoms of benzodiazepine addiction include drowsiness, confusion, impaired coordination, and cravings for higher doses. Over time, when people try to stop using the drug, they experience withdrawal symptoms such as anxiety, insomnia, and seizures.

Benzodiazepine addiction develops out of prolonged use, dose escalation, and misuse of a prescription, and an untreated anxiety disorder or depressive disorder underneath the prescription raises the risk further.

Treatment of benzodiazepine use disorder starts with a medically supervised taper, because abrupt discontinuation precipitates withdrawal seizures and delirium that kill people. A hospital, a detoxification program or the prescribing physician manages that taper. Cognitive behavioral therapy, non-benzodiazepine pharmacotherapy for the underlying anxiety or insomnia, and structured relapse prevention carry the work afterward.

What is a Benzodiazepine?

Benzodiazepine addiction is the compulsive use of benzodiazepines despite harmful consequences, driven by tolerance and physical dependence at the GABA-A receptor. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies it as Sedative, Hypnotic, or Anxiolytic Use Disorder, and diagnosis requires at least 2 of 11 criteria within a 12-month period, among them failed attempts to cut down, craving, and continued use despite social, occupational or physical harm. DSM-5 excludes tolerance and withdrawal from the criteria count when the medication is taken as prescribed under medical supervision, which is why a patient who is physically dependent on a prescribed benzodiazepine does not automatically meet the diagnosis.

Lader, Malcolm (2011) "Benzodiazepines revisited - will we ever learn?", published in Addiction volume 106, pages 2086 to 2109, concluded that "The risk-benefit ratio of the benzodiazepines remains positive in most patients in the short term (2-4 weeks)" and is unestablished beyond that window, because short courses extend indefinitely in practice. Ashton, Heather (1995) "Toxicity and Adverse Consequences of Benzodiazepine Use", Psychiatric Annals volume 25, pages 158 to 165, documented that dependence risk rises with duration of use and with a prior history of substance use disorder.

How Common is Benzodiazepine Addiction?

Benzodiazepine use is common and misuse is not rare. Maust, Donovan T., Lin, Lewei A., and Blow, Frederic C. (2019) "Benzodiazepine Use and Misuse Among Adults in the United States", published in Psychiatric Services volume 70, pages 97 to 106, analyzed National Survey on Drug Use and Health data and found that 30.6 million adults, 12.6% of the adult population, reported past-year benzodiazepine use, with 5.3 million of them, 2.2%, reporting misuse.

Prescribing volume sets the scale of exposure. The Food and Drug Administration reported that 92 million benzodiazepine prescriptions were dispensed from United States outpatient retail and mail-order pharmacies in 2019, led by alprazolam at 38%, clonazepam at 24% and lorazepam at 20%.

What is the History of Benzodiazepines?

Sternbach, Leo, a chemist at Hoffmann-La Roche, identified chlordiazepoxide in 1955, and Roche brought it to market as Librium in 1960 as an alternative to the barbiturates, which have a narrow therapeutic index. Diazepam followed in 1963 under the brand name Valium.

Lorazepam reached the United States market as Ativan in 1977 and alprazolam as Xanax in 1981. The Food and Drug Administration had already approved clonazepam as Klonopin in June 1975 for seizure disorders. Successive agents differed in absorption rate and half-life rather than in mechanism, and every one of them acts at the same GABA-A receptor complex.

What are examples of benzodiazepines?

Alprazolam (Xanax), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), temazepam (Restoril), triazolam (Halcion) and chlordiazepoxide (Librium) are seven benzodiazepines marketed in the United States, each with its own FDA-approved indications and its own elimination half-life.

Elimination half-life is the time a drug's plasma concentration falls by half, and it organizes this class better than any other attribute. Half-life sets the dosing interval, determines whether repeated doses accumulate, and predicts how severe withdrawal becomes. The following 7 benzodiazepines run from shortest to longest half-life, using the figure stated in each product's FDA-approved labeling.

• Triazolam (Halcion): Halcion labeling reports a mean plasma elimination half-life of 1.5 to 5.5 hours, the shortest of the group. Triazolam treats short-term insomnia, and its rapid offset produces rebound insomnia and early-morning anxiety once the dose clears.
• Temazepam (Restoril): Restoril labeling reports a terminal half-life of 3.5 to 18.4 hours, mean 8.8 hours, and no active metabolites. Temazepam treats insomnia, and the absence of active metabolites means no downstream compound extends its clearance the way N-desmethyldiazepam extends diazepam's.
• Alprazolam (Xanax): Xanax labeling reports a mean plasma elimination half-life of 11.2 hours, range 6.3 to 26.9 hours. Alprazolam treats generalized anxiety disorder and panic disorder, and it accounted for 38% of the 92 million benzodiazepine prescriptions dispensed in 2019, the largest share in the class. Xanax addiction tracks that short interval: plasma levels fall between doses, and the interdose trough reproduces the anxiety the prescription was written for.
• Lorazepam (Ativan): Ativan labeling reports a mean half-life of about 12 hours for unconjugated lorazepam and about 18 hours for lorazepam glucuronide, its inactive metabolite. Lorazepam is conjugated rather than oxidized in the liver, so hepatic impairment disturbs its clearance less than it disturbs diazepam's.
• Chlordiazepoxide (Librium): Librium labeling reports a half-life of 24 to 48 hours, and plasma levels decline over several days after the final dose. Chlordiazepoxide treats anxiety and manages acute alcohol withdrawal.
• Clonazepam (Klonopin): Klonopin labeling reports an elimination half-life of 30 to 40 hours with dose-independent kinetics. The Food and Drug Administration approved clonazepam in June 1975 for seizure disorders and later for panic disorder, and clonazepam accounted for 24% of benzodiazepine prescriptions dispensed in 2019.
• Diazepam (Valium): Valium labeling reports a terminal elimination half-life of up to 48 hours for diazepam itself and up to 100 hours for N-desmethyldiazepam, its active metabolite. That metabolite gives Valium addiction a distinct presentation, because sedation accumulates across days of repeated dosing instead of peaking and passing within hours.

Half-life also predicts how long each drug stays measurable in blood and urine, which is why detection windows differ across the class.

What are long acting benzodiazepines?

Long acting benzodiazepines are the members of the class with elimination half-lives of 24 hours or longer: chlordiazepoxide at 24 to 48 hours, clonazepam at 30 to 40 hours, and diazepam at up to 48 hours, per the FDA-approved labeling for Librium, Klonopin and Valium. Diazepam's active metabolite N-desmethyldiazepam extends its reach to about 100 hours.

Duration of action is not a filing convention. It changes how a benzodiazepine is prescribed and, more consequentially, how it is stopped. Every benzodiazepine binds the same allosteric site on the GABA-A receptor complex, so members of the class are cross-tolerant: an equivalent dose of one substitutes pharmacologically for another. A long half-life flattens the plasma curve and removes the sharp declines in receptor occupancy that drive interdose withdrawal. Clinicians use both properties at once, converting a person taking a short-acting benzodiazepine onto an equivalent dose of a long-acting one before reducing the total dose at all.

Brunner, Emily and colleagues (2025) "Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits", published in the Journal of General Internal Medicine volume 40, pages 2814 to 2859 on behalf of 10 medical societies, states that clinicians can transition patients without contraindications to a comparable dose of a longer-acting benzodiazepine for the taper, weighing the pharmacokinetic properties of the drug to avoid sharp declines in receptor occupancy. The same guideline sets initial reductions at 5% to 10% of the total daily dose and caps the pace at 25% every 2 weeks. A prescriber sets and supervises every step of it.

Arithmetic explains why withdrawal timelines diverge inside one drug class. Five elimination half-lives clear about 97% of a dose, so triazolam at the top of its 5.5-hour range is 97% cleared within 28 hours, while diazepam and its 100-hour active metabolite take weeks. Withdrawal from a long-acting benzodiazepine therefore starts later, peaks later and runs longer than withdrawal from a short-acting one.

What are the Symptoms of Benzo Addiction?

The 7 symptoms of benzo addiction are intense cravings, escalating doses, mood instability, rebound anxiety, non-medical use, cognitive impairment and failed attempts to stop. The following 7 symptoms map onto the DSM-5 criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder.

• Intense cravings: Cravings are an overwhelming urge to take a benzodiazepine once no medical indication remains, and craving is what separates a use disorder from ordinary physical dependence. Mol, Annemieke J. and colleagues (2006) "The absence of benzodiazepine craving in a general practice benzodiazepine discontinuation trial", published in Addictive Behaviors, measured craving in long-term primary-care users through a supervised taper and found it largely absent in that group. Craving in a benzodiazepine user therefore marks a diagnosable disorder rather than dependence alone.
• Escalating doses: Escalating doses follow tolerance, which develops as the receptor system adapts and the previous dose stops producing the previous effect. Ashton, Heather (1995) documented this loss of hypnotic and anxiolytic effect across weeks of continuous dosing. Each escalation raises overdose risk, deepens physical dependence and intensifies the withdrawal that follows.
• Mood instability: Mood instability is abrupt, unpredictable shifting between emotional states. Tan, Kelly R. and colleagues (2010) "Neural bases for addictive properties of benzodiazepines", published in Nature volume 463, pages 769 to 774, showed that benzodiazepines disinhibit dopamine neurons of the ventral tegmental area through alpha1-containing GABA-A receptors on neighboring interneurons, the same reward circuit other addictive drugs recruit. Repeated dosing destabilizes that circuit, so euphoria alternates with irritability, low mood or aggression as each dose clears.
• Rebound anxiety: Rebound anxiety is anxiety returning above its pretreatment intensity as the drug clears. Lader, Malcolm (2011) described the effect during withdrawal and between doses of short-acting agents. The person then takes the next dose to relieve anxiety the previous dose created, and that loop converts a prescription into a dependence.
• Non-medical use: Non-medical use is taking a benzodiazepine for sedation or euphoria rather than for a diagnosed indication, frequently alongside alcohol or an opioid. Combination use is where the fatal risk sits: 92.7% of benzodiazepine-involved overdose deaths in the first half of 2020 also involved an opioid, per the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
• Cognitive impairment: Cognitive impairment in long-term benzodiazepine use affects memory, sustained attention and psychomotor speed. Ashton, Heather (1995) documented anterograde amnesia and impaired memory consolidation in long-term users, with older adults most affected. Ashton's companion paper the same year, "Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome" in Psychiatric Annals volume 25, described cognitive symptoms persisting for months after the final dose.
• Failed attempts to stop: Failed attempts to stop are repeated efforts that end in resumption. The Ashton Manual, "Benzodiazepines: How They Work and How to Withdraw", identifies inability to reduce or stop despite repeated attempts as a hallmark of benzodiazepine dependence and attributes it to withdrawal symptoms including anxiety, insomnia, muscle pain and seizures. Unassisted stopping fails because the withdrawal is medically dangerous, not because the person lacks resolve.

What are the Effects of Benzo Addiction?

The 7 effects of benzo addiction are increased tolerance, compulsive use, loss of control, doctor shopping, physical health problems, mental health problems and severe withdrawal symptoms. Each effect is detailed below.

• Increased tolerance: Tolerance builds as the GABA-A receptor system downregulates in response to continuous dosing, so the original dose stops working. Higher doses restore the effect briefly and raise the overdose risk permanently.
• Compulsive use: Compulsive use is dosing that continues after the medical reason for it has ended. The urge overrides the person's own decision to stop, which is the behavioral core of a substance use disorder.
• Loss of control: Loss of control appears as doses taken earlier, larger or more frequently than prescribed. Obtaining and taking the drug then displaces work, family and financial obligations.
• Doctor shopping: Doctor shopping is collecting benzodiazepine prescriptions from providers who are unaware of one another. The New Jersey Prescription Monitoring Program requires pharmacies to report every dispensed Schedule II through V controlled substance within one business day, under N.J.S.A. 45:1-45, so overlapping benzodiazepine prescriptions are visible to any prescriber who queries the database, and stacked prescriptions multiply the overdose risk.
• Physical health problems: Physical effects of chronic benzodiazepine use include muscle weakness, impaired motor coordination, daytime sedation and depressed respiration. Falls and motor vehicle crashes follow from the coordination and reaction-time deficits.
• Mental health problems: Chronic benzodiazepine use worsens the anxiety and depression the prescription was written to relieve. Ashton, Heather (1995) documented emotional blunting and depressed mood as adverse effects of long-term use, and both compound the anxiety rebound that occurs between doses.
• Severe withdrawal symptoms: Reducing or stopping a benzodiazepine produces withdrawal that includes insomnia, panic attacks, tremor, delirium and seizures. Those seizures are why unsupervised discontinuation is dangerous rather than merely uncomfortable.

What are the Causes of Benzodiazepine Addiction?

The 9 causes of benzodiazepine addiction are prescription and medical use, tolerance, underlying mental health conditions, ease of access, self-medication, psychological factors, lack of patient education, environmental factors and co-occurring disorders. These 9 causes are detailed below.

• Prescription and medical use: Benzodiazepine addiction begins with a legitimate prescription for anxiety or insomnia in most cases. Maust, Lin and Blow (2019) counted 25.3 million United States adults, 10.4% of the adult population, taking benzodiazepines exactly as prescribed against 5.3 million misusing them, and FDA-approved labeling states that physical dependence develops after several days to weeks of steady use even inside that prescribed group.
• Tolerance: Tolerance to the sedative and anxiolytic effects appears within weeks of continuous dosing, per FDA-approved labeling for the class. The dose then climbs to restore the original effect, and each increase enlarges the dependence that has to be tapered later.
• Underlying mental health conditions: Anxiety disorders, major depressive disorder and PTSD are the conditions benzodiazepines get prescribed for, and each keeps generating the symptom the drug suppresses. Left untreated, the underlying condition guarantees continued demand for the medication.
• Ease of access: Access is wide. The Food and Drug Administration reported 92 million benzodiazepine prescriptions dispensed from United States outpatient retail and mail-order pharmacies in 2019, and household supplies from those prescriptions reach people who never saw a prescriber.
• Self-medication: Self-medication is using a benzodiazepine obtained without a prescription to manage stress, panic or sleeplessness. Daily use follows quickly, because the drug works on the first dose while the tolerance that erodes that effect stays invisible for weeks.
• Psychological factors: Psychological factors that raise benzodiazepine risk include chronic stress, trauma exposure and a prior substance use disorder. Reliance on a sedative as the primary coping strategy for emotional distress converts intermittent use into daily use.
• Lack of patient education: Patients prescribed a benzodiazepine are frequently not told that dependence forms within weeks. The Food and Drug Administration required updated Medication Guides and Patient Counseling Information alongside the 2020 class-wide boxed warning specifically to close that gap, which means the regulator documented the gap itself.
• Environmental factors: Environmental factors include social pressure, benzodiazepine use inside the household, and sustained exposure to high-stress conditions. Household access matters most, because a prescription written for one family member supplies another with no clinical contact at all.
• Co-occurring disorders: Co-occurring disorders raise benzodiazepine risk because the sedative relieves the symptom the untreated psychiatric condition keeps generating. Sedative, Hypnotic, or Anxiolytic Use Disorder sits alongside anxiety, depressive and trauma diagnoses in the same patients, and treating one while ignoring the other leaves the driver of use in place.

What Are The Treatment Options for Benzo Addiction?

The treatment options for benzodiazepine addiction include behavioral therapies, group therapy, medications, rehab centers, and inpatient treatments.

Valley Spring Recovery Center in Norwood, New Jersey provides the outpatient portion of that list through its benzodiazepine addiction treatment programs and not the withdrawal management. Valley Spring does not provide detoxification, inpatient or residential care, so a prescriber, a detoxification program or a hospital runs the supervised taper first. Restore Partial Care, which admits under New Jersey substance use license #200887, then steps down to Activate intensive outpatient and to Accelerate outpatient, with the Thrive alumni community and a dedicated Mental Health Track alongside. Admissions answer at (855) 924-5320.

The following 5 treatment components make up benzodiazepine addiction treatment in United States practice.

• Behavioral therapies: Cognitive behavioral therapy restructures the thoughts and behaviors that maintain benzodiazepine use and builds non-pharmacological management of anxiety and insomnia. CBT for insomnia replaces the function the hypnotic was serving, which is what makes discontinuation hold. Courses run weekly across several months and require active participation.
• Group therapy: Group therapy puts a person in a room with others tapering or abstinent from the same class of drug, which supplies accountability that individual sessions cannot. Groups meet weekly inside a longer treatment plan. Group work is less individualized than one-to-one therapy and complements it rather than replacing it.
• Medications: Medication management in benzodiazepine treatment covers two jobs: the prescriber-run taper itself, and non-benzodiazepine treatment of the anxiety or insomnia underneath it. Selective serotonin reuptake inhibitors, buspirone and behavioral sleep interventions take over the original indication so the taper has somewhere to land.
• Rehab centers: Residential and outpatient programs deliver structured therapy, case management and aftercare planning around the medical taper. Level of care determines program length and cost, and a program that admits someone in benzodiazepine withdrawal needs prescriber coverage for the taper.
• Inpatient treatment: Inpatient treatment provides 24-hour monitoring inside a facility, which benzodiazepine withdrawal warrants when the daily dose is high, the use history is long, or a seizure disorder or other medical condition raises the stakes. Discharge from inpatient care steps down to intensive outpatient rather than to nothing.

How to Prevent Benzodiazepine Addiction?

Preventing benzodiazepine dependence means keeping the course short, taking only the prescribed dose, and never adding an opioid or alcohol. The Food and Drug Administration imposed the 2020 class-wide boxed warning precisely because dependence forms inside ordinary prescribed use, which puts an agreed end date on the same footing as the dose. Ask the prescriber at the first appointment how the drug will be stopped and on what schedule, because a taper written at the start is easier to follow than one improvised after dependence has formed.

Recognizing the early pattern matters as much as the prescribing. Rising tolerance, dosing aimed at sleep or stress rather than the original indication, and anxiety that returns between doses each mark the transition from therapeutic use toward a use disorder. Report escalating dose need, or the urge to seek an early refill, to the original prescriber rather than to a second one.

What happens in a benzodiazepine overdose?

A benzodiazepine overdose depresses the central nervous system, producing profound sedation, impaired coordination, slurred speech, respiratory depression, coma and death. Risk climbs steeply when a benzodiazepine is combined with an opioid, with alcohol, or with another central nervous system depressant.

FDA-approved labeling for the entire class carries a boxed warning, the agency's strongest, on that combination. The Xanax label states that "Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death." The Food and Drug Administration imposed that warning across nearly 400 opioid and benzodiazepine products in 2016, then required a second class-wide boxed warning in 2020 covering abuse, misuse, addiction, physical dependence and withdrawal reactions.

Federal mortality data show how completely this is a polysubstance risk. Liu, Stephen and colleagues (2021) "Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines: 38 States and the District of Columbia, 2019-2020", published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report volume 70, pages 1136 to 1141, found that 92.7% of benzodiazepine-involved overdose deaths during January to June 2020 also involved an opioid, and 66.7% involved illicitly manufactured fentanyls. The same analysis recorded a 519.6% increase in deaths involving illicit benzodiazepines such as etizolam, flualprazolam and flubromazolam between the second quarter of 2019 and the second quarter of 2020, against a 21.8% increase for prescription benzodiazepines. Those three compounds are ingredients in no FDA-approved medicine and reach people through pills obtained outside a pharmacy.

Reversal is where benzodiazepines diverge from opioids in a way that costs lives. Naloxone, marketed as Narcan, is an opioid antagonist that FDA-approved labeling indicates for the emergency treatment of known or suspected opioid overdose. Naloxone occupies opioid receptors and has no activity at the benzodiazepine site on the GABA-A receptor, so naloxone does not reverse a benzodiazepine. Naloxone still belongs at every suspected overdose, because 92.7% of benzodiazepine-involved deaths carry an opioid that naloxone does reverse. Flumazenil, the benzodiazepine receptor antagonist the Food and Drug Administration approved in 1992, is not this class's equivalent of naloxone: its labeling carries a boxed warning for seizures, concentrated in people who are physically dependent on benzodiazepines and in people who have taken a mixed overdose. Emergency clinicians treat benzodiazepine overdose with airway management and monitoring. Call 911 for a suspected overdose.

Why is it dangerous to stop taking benzodiazepines abruptly?

Abrupt benzodiazepine discontinuation precipitates seizures and delirium, and those withdrawal reactions kill people. The boxed warning in FDA-approved labeling states that "Abrupt discontinuation or rapid dosage reduction of XANAX after continued use may precipitate acute withdrawal reactions, which can be life-threatening."

Physical dependence forms faster than most patients are told. The Food and Drug Administration's 2020 class-wide boxed warning update states that physical dependence develops after several days to weeks of steady use, even at a therapeutic dose taken exactly as directed. Xanax labeling further documents a protracted withdrawal syndrome, with symptoms lasting weeks to more than 12 months in some patients.

Medically supervised withdrawal is the answer, and it belongs before outpatient treatment rather than inside it. The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering directs clinicians to avoid abruptly discontinuing benzodiazepines in patients likely to be physically dependent, because rapid dose reduction causes life-threatening withdrawal symptoms including seizures and delirium. A hospital, a detoxification program or the prescribing physician runs that taper, and outpatient treatment picks up once the taper is stable.

How is Benzodiazepine Addiction Different From Other Types of Drug Addictions?

Benzodiazepine addiction differs from other forms of drug addiction in one decisive respect: withdrawal from the drug itself causes fatal seizures. Benzodiazepine withdrawal produces seizures and delirium, a hazard it shares with alcohol withdrawal and one absent from opioid and stimulant withdrawal, which are severe without threatening life in otherwise healthy adults. Tolerance also develops within weeks of continuous therapeutic dosing, per FDA-approved labeling for the class.

What is the difference between benzodiazepines and opioids?

Benzodiazepines and opioids differ in receptor target, clinical purpose and withdrawal danger. Benzodiazepines bind an allosteric site on the GABA-A receptor to amplify inhibition, treat anxiety, panic disorder and insomnia, and produce withdrawal that includes fatal seizures.

Opioids bind mu-opioid receptors to block pain signaling and produce euphoria, and prescribers use them for pain. Opioid use disorder is sustained by those reinforcing effects and by avoidance of withdrawal, which brings severe pain, diarrhea and craving without seizures. Combining the two classes carries the FDA boxed warning for profound sedation, respiratory depression, coma and death.